IGF1R Induces ROS Formation in Mitochondria via MICU1 Leads to the Enzalutamide Resistance in Prostate Cancer

IF 4.7
Hanlin Li, Yutong Chen, Yupeng Zhou, Yang Li, Yukui Gao, Xuanrong Chen, Qianwang Ma, Shimiao Zhu, Simeng Wen
{"title":"IGF1R Induces ROS Formation in Mitochondria via MICU1 Leads to the Enzalutamide Resistance in Prostate Cancer","authors":"Hanlin Li,&nbsp;Yutong Chen,&nbsp;Yupeng Zhou,&nbsp;Yang Li,&nbsp;Yukui Gao,&nbsp;Xuanrong Chen,&nbsp;Qianwang Ma,&nbsp;Shimiao Zhu,&nbsp;Simeng Wen","doi":"10.1111/jcmm.71415","DOIUrl":null,"url":null,"abstract":"<p>After undergoing ADT treatment, drug resistance has emerged as a major hindrance in the treatment of prostate cancer, with enzalutamide resistance being the most notable. Our objective was to identify a new drug-resistance mechanism present in post-ADT-treatment patients. Utilizing proteomic sequencing, we discovered abnormal increases in IGF1R levels. Subsequent sequencing and bioinformatic analyses showed that IGF1R could cause abnormal changes in the tricarboxylic acid cycle (TCA cycle) and oxidative phosphorylation. This phenomenon may be due to IGF1R's influence on the distribution of mitochondrial Ca<sup>2+</sup> and the production of reactive oxygen species (ROS). Our CHIP and dual-luciferase experiments confirmed the regulatory relationship between IGF1R and MICU1. The fluorescent results of Ca<sup>2+</sup> and ROS also confirmed that IGF1R could regulate mitochondrial Ca<sup>2+</sup> distribution and ROS production. Our team validated the relationship between IGF1R and drug resistance through cell phenotype experiments, and explored its potential as a therapeutic target through a fa-ci curve. Finally, we verified the effectiveness of the mechanisms we found through a xenograft assay. Our study confirms the potential for IGF1R as a clinical therapeutic target.</p>","PeriodicalId":101321,"journal":{"name":"JOURNAL OF CELLULAR AND MOLECULAR MEDICINE","volume":"30 20","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jcmm.71415","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JOURNAL OF CELLULAR AND MOLECULAR MEDICINE","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jcmm.71415","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

After undergoing ADT treatment, drug resistance has emerged as a major hindrance in the treatment of prostate cancer, with enzalutamide resistance being the most notable. Our objective was to identify a new drug-resistance mechanism present in post-ADT-treatment patients. Utilizing proteomic sequencing, we discovered abnormal increases in IGF1R levels. Subsequent sequencing and bioinformatic analyses showed that IGF1R could cause abnormal changes in the tricarboxylic acid cycle (TCA cycle) and oxidative phosphorylation. This phenomenon may be due to IGF1R's influence on the distribution of mitochondrial Ca2+ and the production of reactive oxygen species (ROS). Our CHIP and dual-luciferase experiments confirmed the regulatory relationship between IGF1R and MICU1. The fluorescent results of Ca2+ and ROS also confirmed that IGF1R could regulate mitochondrial Ca2+ distribution and ROS production. Our team validated the relationship between IGF1R and drug resistance through cell phenotype experiments, and explored its potential as a therapeutic target through a fa-ci curve. Finally, we verified the effectiveness of the mechanisms we found through a xenograft assay. Our study confirms the potential for IGF1R as a clinical therapeutic target.

Abstract Image

IGF1R通过MICU1诱导线粒体ROS形成导致前列腺癌对恩杂鲁胺耐药
在接受ADT治疗后,耐药已成为前列腺癌治疗的主要障碍,其中以恩杂鲁胺耐药最为显著。我们的目的是确定adt治疗后患者出现的一种新的耐药机制。利用蛋白质组学测序,我们发现IGF1R水平异常升高。随后的测序和生物信息学分析表明,IGF1R可引起三羧酸循环(TCA循环)和氧化磷酸化的异常变化。这种现象可能是由于IGF1R影响线粒体Ca2+的分布和活性氧(ROS)的产生。我们的CHIP和双荧光素酶实验证实了IGF1R和MICU1之间的调控关系。Ca2+和ROS的荧光结果也证实了IGF1R可以调节线粒体Ca2+的分布和ROS的产生。我们的团队通过细胞表型实验验证了IGF1R与耐药之间的关系,并通过fa-ci曲线探索了其作为治疗靶点的潜力。最后,我们通过异种移植试验验证了我们发现的机制的有效性。我们的研究证实了IGF1R作为临床治疗靶点的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
11.50
自引率
0.00%
发文量
0
期刊介绍: The Journal of Cellular and Molecular Medicine serves as a bridge between physiology and cellular medicine, as well as molecular biology and molecular therapeutics. With a 20-year history, the journal adopts an interdisciplinary approach to showcase innovative discoveries. It publishes research aimed at advancing the collective understanding of the cellular and molecular mechanisms underlying diseases. The journal emphasizes translational studies that translate this knowledge into therapeutic strategies. Being fully open access, the journal is accessible to all readers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书